Brokerages forecast that Integra LifeSciences Holdings Corporation (NASDAQ:IART) will report sales of $361.17 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Integra LifeSciences Holdings Corporation’s earnings. The lowest sales estimate is $346.00 million and the highest is $409.80 million. Integra LifeSciences Holdings Corporation reported sales of $255.66 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 41.3%. The firm is expected to issue its next quarterly earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that Integra LifeSciences Holdings Corporation will report full year sales of $361.17 million for the current year, with estimates ranging from $1.17 billion to $1.23 billion. For the next financial year, analysts expect that the business will report sales of $1.47 billion per share, with estimates ranging from $1.44 billion to $1.51 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The company had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. During the same quarter in the previous year, the business posted $0.93 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis.

A number of research firms have recently weighed in on IART. Royal Bank of Canada restated a “sector perform” rating and issued a $50.00 price target (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday. UBS AG reiterated a “buy” rating and issued a $57.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, October 31st. Wells Fargo & Company lowered shares of Integra LifeSciences Holdings Corporation from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. Jefferies Group LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Sunday, October 29th. Finally, TheStreet lowered shares of Integra LifeSciences Holdings Corporation from a “b” rating to a “c+” rating in a report on Thursday, October 26th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $53.82.

In other news, Director Barbara B. Hill purchased 10,768 shares of the stock in a transaction on Tuesday, October 31st. The stock was purchased at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the acquisition, the director now owns 55,540 shares in the company, valued at $2,591,496.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 21.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in IART. Capital Research Global Investors raised its holdings in Integra LifeSciences Holdings Corporation by 227.0% during the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock worth $212,441,000 after purchasing an additional 2,705,488 shares during the last quarter. Janus Henderson Group PLC bought a new position in Integra LifeSciences Holdings Corporation during the 2nd quarter worth approximately $112,068,000. State Street Corp raised its holdings in Integra LifeSciences Holdings Corporation by 116.5% during the 1st quarter. State Street Corp now owns 1,497,043 shares of the life sciences company’s stock worth $63,070,000 after purchasing an additional 805,426 shares during the last quarter. Koch Industries Inc. raised its holdings in Integra LifeSciences Holdings Corporation by 12,623.4% during the 2nd quarter. Koch Industries Inc. now owns 754,880 shares of the life sciences company’s stock worth $741,000 after purchasing an additional 748,947 shares during the last quarter. Finally, FMR LLC raised its holdings in Integra LifeSciences Holdings Corporation by 6.2% during the 2nd quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock worth $440,690,000 after purchasing an additional 468,678 shares during the last quarter. Hedge funds and other institutional investors own 84.10% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at $47.59 on Friday. Integra LifeSciences Holdings Corporation has a one year low of $37.71 and a one year high of $56.42. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The firm has a market cap of $3,833.62, a P/E ratio of 26.99, a PEG ratio of 2.14 and a beta of 0.64.

ILLEGAL ACTIVITY WARNING: “Integra LifeSciences Holdings Corporation (IART) Expected to Announce Quarterly Sales of $361.17 Million” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/12/integra-lifesciences-holdings-corporation-iart-expected-to-announce-quarterly-sales-of-361-17-million.html.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.